| 发明名称 | Methods and peptides for preventing and treating a BCR-ABL and a C-ABL associated disease | ||
| 摘要 | The invention provides a combination of an isolated peptide or peptidomimetic that includes the sequence of SEQ ID NO: 1 or a homolog thereof, and an isolated peptide or peptidomimetic that includes the sequence of SEQ ID NO: 2. The invention also provides a method of treating a BCR-ABL associated disease or a c-ABL associated disease in a subject. The method is based on the use of the aforementioned combination of one or more isolated peptides or peptidomimetics. | ||
| 申请公布号 | US9637523(B2) | 申请公布日期 | 2017.05.02 |
| 申请号 | US201314422918 | 申请日期 | 2013.08.30 |
| 申请人 | Westfaelische Wilhelms-Universitaet Muenster | 发明人 | Hrincius Eike-Roman;Ludwig Stephan;Ehrhardt Christina |
| 分类号 | A61K38/00;C07K14/005;A61P35/02;C07K14/82;A61K38/16;C12Q1/48;C12N9/12;G01N33/50;A61K48/00 | 主分类号 | A61K38/00 |
| 代理机构 | Riverside Law LLP | 代理人 | Riverside Law LLP |
| 主权项 | 1. A method of treating a BCR-ABL associated disease or a c-ABL associated disease selected from the group consisting of chronic myeloid leukaemia (CML), acute lymphatic leukaemia (ALL), acute myeloic leukaemia (AML) and a c-ABL associated leukemia in a subject in need thereof, the method comprising administering to the subject a nonstructural protein 1 (NS1), wherein the NS1 protein comprises the amino acid sequence of SEQ ID NO: 1 and PPX13PX1X16 (SEQ ID NO: 107), wherein X1 is any amino acid, X13 is selected from the group consisting of A, C, G, I, L, M, F, P, W and V, and X16 is K or R. | ||
| 地址 | Muenster DE | ||